PFC
AXSM icon

Phocas Financial Corp’s Axsome Therapeutics AXSM Stock Holding History

Phocas Financial Corp’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,588
Closed -$1.93M – 145
2025
Q1 		$1.93M Sell
16,588
-958
-5% -$109K 0.3% 105
2024
Q4 		$1.49M Buy
+17,546
New +$1.61M 0.2% 119
2023
Q4 		$2.14M Buy
+26,890
New +$1.8M 0.28% 114

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Phocas Financial Corp's AXSM Position: Q2 2025 in Review

Phocas Financial Corp sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 16,588 shares — an estimated $1.93M sold.

Phocas Financial Corp first reported a position in AXSM in Q4 2023 and held it in 3 quarters. The position peaked at $2.14M in Q4 2023. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

  • Phocas Financial Corp reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Phocas Financial Corp sold 16,588 Axsome Therapeutics shares in Q2 2025, an estimated $1.93M.
  • Phocas Financial Corp first reported a position in Axsome Therapeutics in Q4 2023 and held it in 3 quarters.
  • Phocas Financial Corp's Axsome Therapeutics position peaked at $2.14M in Q4 2023.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on Phocas Financial Corp's 13F filing for Q2 2025, filed 6 Aug 2025.